HSR22-162: Budget Impact Analysis of Abemaciclib in Combination With Endocrine Therapy (ET) in Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-), Node-Positive Early Breast Cancer (EBC) at High Risk of Recurrence and Ki-67 Score ≥20%

Subjects

Subjects :

Oncology

Details

ISSN :

15401413 and 15401405

Volume :

20

Database :

OpenAIRE

Journal :

Journal of the National Comprehensive Cancer Network

Accession number :

edsair.doi...........881dcd065f82e28c69efc0c15584c094

Full Text :

https://doi.org/10.6004/jnccn.2021.7222